BRAF and melanoma: The NGS technique, including the WES approach, has also been explored as a biomarker in studies with advanced melanoma patients treated with BRAF/MEKi or ICI; however, neither of the studies reviewed found a relationship between ctDNA levels and treatment efficacy or prognosis, probably due to small sample sizes.